Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered donor cells take aim at tough blood cancers in early trial

NCT ID NCT05377827

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modified to target a protein called CD7 on cancer cells, while avoiding attacking each other or causing graft-versus-host disease. The main goals are to check safety and find the best dose, with only 6 participants enrolled so far.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

WU-CART-007 (a type of immune cell therapy made from donor cells, engineered to target CD7 on cancer cells)

What this could lead to

If successful, this could offer a new treatment option for people with hard-to-treat blood cancers that have not responded to standard therapies.

What could go wrong

This is a very early, small Phase 1 trial with only 6 participants, so results may not apply broadly. There are risks of serious side effects, and the therapy may not work or may cause long-term immune problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma enteropathy-associated T-cell lymphoma extranodal nasal NK/T cell lymphoma hepatosplenic T-cell lymphoma Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma monomorphic epitheliotropic intestinal T-cell lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma primary cutaneous gamma-delta t-cell lymphoma Sezary syndrome T-cell non-Hodgkin lymphoma T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ADULT T CELL LEUKEMIA ADULT T CELL LYMPHOMA ANAPLASTIC LARGE CELL LYMPHOMA ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA EXTRANODAL NK/T-CELL LYMPHOMA HEPATOSPLENIC T-CELL LYMPHOMA MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA PERIPHERAL T CELL LYMPHOMA PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA SEZARY SYNDROME T-CELL NON-HODGKIN LYMPHOMA T-CELL PROLYMPHOCYTIC LEUKEMIA TRANSFORMED MYCOSIS FUNGOIDES

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States